Expert Interview
Discussing Ipsen's Phase 3 data from the ELMWOOD study of elafibranor in patients with primary sclerosing cholangitis (PSC)
Ticker(s): IPSEY, IPN.XPARInstitution: MUSC
- Professor and Chairman of our Department of Medicine at MUSC.
- Clinical research interests revolve around establishing management strategies for patients with common gastrointestinal problems, especially GI bleeding, and the overall direction of these studies has been to help establish national patient management guidelines.
- Has authored more than 200 scientific papers dealing with GI-related topics and has presented many invited lectures at gastroenterology and hepatology symposia around the United States and throughout the world.
How frequently do you manage or consult on cases of primary sclerosing cholangitis (PSC) in your clinical practice?
Added By: sara_adminCan you discuss elafibranor’s mechanism of action and its potential therapeutic role in cholestatic liver diseases like PSC?
Added By: sara_adminBased on the available data, how would you compare elafibranor’s efficacy and safety profile to other investigational therapies or off-label treatments currently used for PSC?
Added By: sara_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
